Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXM34I)

Drug Name
O-304 Drug Info
Synonyms
1261289-04-6; O304; 4-chloro-N-(2-(4-chlorobenzyl)-3-oxo-2,3-dihydro-1,2,4-thiadiazol-5-yl)benzamide; 4-chloro-N-[2-[(4-chlorophenyl)methyl]-2,3-dihydro-3-oxo-1,2,4-thiadiazol-5-yl]-benzamide; SCHEMBL1050337; BCP29039; EX-A1990; MFCD31657425; 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide; BS-14854; HY-112233; CS-0044210; O 304; S0795
Indication
Disease Entry ICD 11 Status REF
Type 2 diabetes 5A11 Phase 2 [1]
Cross-matching ID
PubChem CID
50923806
TTD Drug ID
DMXM34I

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting AMP-activated protein kinase (AMPK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acadesine DM1RMF5 Diabetic complication 5A2Y Phase 3 [3]
MB-11055 DM3RBJW Fatty liver disease DB92.Z Phase 2 [4]
Imeglimin DMMQFG2 Diabetic complication 5A2Y Phase 2 [5]
PXL-770 DMNSRY7 Non-alcoholic fatty liver disease DB92 Phase 2 [6]
ENERGI-F701 DMMIHSO Alopecia ED70 Phase 2 [7]
IM156 DM4MY9C Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
Phenformin DMQ52JG Diabetic complication 5A2Y Withdrawn from market [9]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [10]
PMID23639540C13a DMLXOAQ Discovery agent N.A. Investigative [11]
SU 6656 DMF1P6W Discovery agent N.A. Investigative [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
AMP-activated protein kinase (AMPK) TTLAFZV AAPK1_HUMAN; AAKB1_HUMAN; AAKG1_HUMAN Activator [2]

References

1 Clinical pipeline report, company report or official report of Betagenon.
2 Clinical pipeline report, company report or official report of Betagenon.
3 Acadesine, an adenosine-regulating agent with the potential for widespread indications. Expert Opin Pharmacother. 2008 Aug;9(12):2137-44.
4 Antidiabetes and antiobesity effect of cryptotanshinone via activation of AMP-activated protein kinase.Mol Pharmacol.2007 Jul;72(1):62-72.
5 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032542)
6 Clinical pipeline report, company report or official report of Poxel SA.
7 Clinical pipeline report, company report or official report of Energenesis Biomedical.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Complementary regulation of TBC1D1 and AS160 by growth factors, insulin and AMPK activators. Biochem J. 2008 Jan 15;409(2):449-59.
10 Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
11 Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
12 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.